Inicio Zine News Dance Biopharm Presents Phase 2 Clinical Data Highlighting Rapid Effects of Inhaled...

Dance Biopharm Presents Phase 2 Clinical Data Highlighting Rapid Effects of Inhaled Human Insulin at European Association for the Study of Diabetes Meeting

6
0

DURHAM, N.C., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Dance Biopharm Holdings, Inc., a clinical-stage company reimagining the treatment of chronic diseases with inhaled therapies, today presented data from its Phase 2 clinical study of Dance 501, a novel gentle mist formulation of human insulin administered with its smart inhaler, in patients with type 2 diabetes (T2D). The data were presented at the 55th Annual Meeting of the European Association for the Study of Diabetes on September 19, 2019, in Barcelona, Spain. Study results showed Dance 501 inhaled human insulin (INH) had comparable glucodynamic properties to injected insulin lispro (LIS), but delivered a faster onset of action.